Meeting
2015 ASCO Annual Meeting
Lenalidome in combination with rituximab for relapsed or refractory mantel cell lymphoma: Updated analysis of a phase 2 trial.
Authors
Yucai Wang
Rutgers New Jersey Medical School, Newark, NJ
Yucai Wang , Maria Lourdes Dela Rosa , Shouhao Zhou , Maria Badillo , Alicia Addison , Liang Zhang , Hun Ju Lee , Jorge Enrique Romaguera , Michael Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT00294632
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8542)
DOI
10.1200/jco.2015.33.15_suppl.8542
Abstract #
8542
Poster Bd #
359
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator’s choice in relapsed/refractory mantle cell lymphoma.
First Author: Marek Trneny
Poster
2022 ASCO Annual Meeting
Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.
First Author: Lorenzo Falchi
Poster
2020 ASCO Virtual Scientific Program
Phase I/II study of R-ICE (rituximab-ifosfamide-carboplatin-etoposide) with lenalidomide (R2-ICE) in patients with first-relapse/primary refractory diffuse large B-cell lymphoma (DLBCL) in academic and community cancer research united (ACCRU) network.
First Author: Francis Guerra-Bauman
Poster
2018 ASCO Annual Meeting
Lenalidomide with R-IMED (rituximab, ifosfamide, methotrexate, etoposide and dexamethasone) in refractory or relapsed non-GCB diffuse large B-cell lymphoma: A phase II clinical trial.
First Author: Tongyu Lin